Efficacy endpoints of SCT200 plus SCT-I10A cohort and SCT200 cohort
| Characteristic | SCT200 + SCT-I10A |
|---|---|
| Number of patients | 21 |
| Best tumor response, n (%) | |
| PR, n (%) | 6 (28.57) |
| SD, n (%) | 12 (57.14) |
| PD, n (%) | 3 (14.29) |
| ORR, n (%) | 6 (28.57) |
| DCR, n (%) | 18 (85.71) |
| OS, median (95% CI), months | 12.84 (6.64, 16.06) |
| PFS, median (95% CI), months | 4.14 (2.73, 5.45) |
| DOR, median (95% CI), months | 2.87 (1.54, NA) |
n, number; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; PFS, progression-free survival; OS, overall survival; DOR, duration of response; NA, not available.